top of page


Public·61 members

Mature Breasts Play

British mature Tracey plays with nylon tights and pushes a banana into her milf arse (brand NEW video available in Full HD 1080P). Bonus video: Blonde beauty Lucy Gresty fucks her cunny with a banana.

mature breasts play

The role of adipose tissue in breast development. (A) Mature breast adipose tissue secretes leptin which is essential for ductal epithelial development. High levels of adiponectin inhibit this process. White adipose tissue (WAT) is essential for the formation of terminal end buds (TEBs) during prepuberty and puberty stages. After menarche, the breast starts to mature, and the duct starts its side branching, which requires WAT. (B) During pregnancy, WAT trans differentiates into pink adipose tissue (PAT). PAT has milk secretory potential. The process of trans differentiation from WAT to PAT is carried out by the transcription factor SPP1. Moreover, WAT is also essential for alveolar development during the lactation phase and also for the lactation process. During the phase of pregnancy and lactation, brown adipose tissue (BAT) trans differentiates to a basal myoepithelial phenotype helping in the alveolar development. Both trans differentiated cells revert to their original state after lactation with the aid of the transcription factor PPARγ. (C) There are two stages of breast involution (i) post-lactation and (ii) age-related. SFRP1 secreted by breast adipose tissue helps in these involution processes by the apoptosis of luminal epithelial cells. Furthermore, the epithelial cells are replaced by adipose tissue during the involution process.

The adipogenesis repressors also display mixed roles in BC. GATA-binding factor (GATA) 2 promotes BC by inhibiting PTEN activity [65], while GATA3 acts as a tumor suppressor and is required for the normal development of the mammary gland, specifically luminal epithelial cells [66]. Further, Forkhead Box (Fox) A2 suppresses BC [67], whereas FoxC2 promotes BC [68]. CHOP (C/EBPζ) and Wnt signaling suppress adipogenesis by promoting the differentiation of mesenchymal stem cells into myocytes and osteocytes but blocking the commitment to the adipocyte lineage [69,70]. CHOP correlates with the invasiveness of human colorectal cancer [71], but not much information is reported in BC. Wnt signaling (dependent or independent of CTNNB1) is required for the development of the mammary gland, its branching and functions [72,73,74,75,76,77]. It has been reported that high levels of Catenin Beta 1 (CTNNB1) lead to high tumor grade and poor prognosis in BC patients [78,79,80]. Moreover, Preadipocyte factor 1 (PREF-1), also known as DLK-1, is highly expressed in mesenchymal adipocyte precursors, which are important for the development of embryonic WAT and the expansion of adult adipose tissue [81,82]. During breast development, platelet-derived growth factor (PDGF) receptor α+ (PDGFRα+) and PREF-1+ mesenchymal stem cells, located near the parenchymal epithelium, can differentiate into adipocytes or epithelial cells depending on the stimuli from steroid hormones [83]. PREF-1 has been shown to exert its effect in a dose-dependent manner in BC, where high levels of PREF-1 result in a decrease in cell proliferation and invasion, whereas a low-level expression is necessary for these processes [84]. The role of Sirtuin 1 (SIRT-1) in BC is controversial. Latifkar et a.l, 2019 showed that a knockdown of SIRT-1 changes the secretome of BC cells, leading to increased invasiveness and survival [85]. On the other hand, Jin et al., 2018, showed that SIRT-1 expression leads to tumor promotion by modulating the expression of AKT [86]. Tafazzin (TAZ) is highly expressed in most aggressive BCs and has a role in BC migration, invasion and tumorigenesis [87].

SFRP1 is an adipokine mainly expressed in mature adipocytes with a role in adipogenesis [38]. SFRP1 mediates its effect on adipogenesis in a paracrine manner by inhibiting the Wnt/β-catenin pathway, thereby determining the fate of ADSC to become an adipose tissue [38]. Its expression has been correlated with mild obesity but significantly decreases with morbid obesity. Furthermore, it has been shown that SFRP1 expression decreases the expression of IL-6, MCP-1 and adiponectin, thereby decreasing the pro-inflammatory response of adipose tissue in BC [39]. Klopocki et al., 2004, showed that the loss of SFRP1 leads to poor prognosis in early stage BC [184]. Another study by Gregory et al., 2017, identified a role for SFRP1 in regulating the transcription factor Early Growth Response 2 (EGR2) via the TGFβ pathway [185]; the loss of SFRP1 leads to BC progression by upregulating TGFβ and thereby EGR2 [185].

Interaction between BC cells and adipose tissue in the BC microenvironment. Breast adipose tissue secretes various molecules (green) which increase BC survival, proliferation, migration, angiogenesis and metastasis. These secretomes also help BC cells in evading chemotherapy mediated apoptosis and increase the survival of residual cancer cells after chemotherapy. BC cells also secrete cytokines and chemokines which signal lipolysis of adipose tissue, changing the secretory phenotype of adipose tissue to a cancer-associated phenotype. The cancer associated adipose tissue aids in BC survival by releasing inflammatory cytokines, proteases and providing the energy source in the form of free fatty acids. Studies have identified various approaches to target the crosstalk between BC cells and adipose tissue (indicated in red). By targeting the differentiation of pre-adipose tissue to mature adipose tissue, which can be performed by overexpressing adipogenesis regulatory cells (Aregs stop this differentiation), PDGFRα (changes the fate of pre-adipose tissue to extracellular matrix) or by treatment with Sulforaphane (which stimulates the regeneration of pre-adipocytes and inhibits its differentiation to mature adipocytes). Furthermore, the inhibition of fatty acid transporter 4 (BMO309403) inhibits the transfer of energy from adipose tissue to BC cells. Moreover, the inhibition of CD36 by monoclonal antibody against CD36 leads to the inhibition of fatty acid uptake by BC cells. Another study showed that increasing the expression of PPARγ in BC cells could lead to trans differentiation of BC cells into adipose tissue, thereby inhibiting BC angiogenesis.

Regarding the first approach, a study by Schwalie et al., 2018, reported the presence of adipogenesis regulatory cells (Aregs) in WAT stromal vascular fraction, characterized by high expression of the cell surface protein CD142 and the ATP-binding cassette sub-family G member 1 (ABCG1). In their study, they have shown that Aregs inhibit the differentiation of adipocyte precursor cells (APC) into adipocytes. Triggering the expression of Aregs in the breast adipose tissue population could be a new therapeutic approach [243]. Furthermore, Miwa et al., 2018, showed that APC expresses the PDGFR tyrosine kinase α (PDGFRα), which is absent in mature WAT [244]. The activation of signaling via PDGFRα in APC represses its differentiation into WAT by converting APC to ECM, which could be a potential target in inhibiting adipogenesis [245]. Moreover, a drug called Sulforaphane has been shown to inhibit adipogenesis by activating the self-renewal process of mesenchymal stem cells in BC [246].

As BC is marked by a significant increase in inflammatory molecules both within the tumor and in the microenvironment, anti-inflammatory drugs are being considered with other drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, mefenamic acid, celecoxib, aspirin and diclofenac mediate their action by inhibiting COX (COX-1 and COX-2). COXs are enzymes that play a role in prostaglandins secretion [249], thereby regulating inflammatory processes such as platelet aggregation. Gao et al., 2007, identified 3 variants in COX-2 that, when occurring simultaneously, increase the risk of BC in Chinese women [250]. The use of NSAIDs is still under consideration as it could affect the gastrointestinal tract, the platelet function and increase the risk of cardiovascular diseases [251,252]. Anti-inflammatory molecules used in the treatment of HIV infection are also under investigation in BC. For example, maraviroc, vicroviroc and leronlimab targeting CCR5 are under clinical trial for BC [253]. Furthermore, Cenicriviroc for CCL2 [254], Tocilizumab targeting IL-6R [255], Canakinumab for IL-1β [256], Infliximab and nanoparticle based CYT-6091 (under clinical trial) for TNF-α [257,258] can be used as possible anti-inflammatory molecules in BC.

Breast development is a vital part of puberty in females. It occurs in stages: first before birth, then during puberty, and then again during the childbearing years. Changes also occur to the breasts during menstruation and when a woman reaches menopause.

As a girl reaches puberty, the first visible signs of breast development start to show. When the ovaries start to produce and release (secrete) estrogen, fat in the connective tissue starts to build up. This causes the breasts to enlarge. The duct system also starts to grow. Often, pubic and underarm hair also appear at this time.

Once ovulation and menstruation start, the breasts begin to mature and glands form at the end of the milk ducts. The breasts and duct system continue to grow and mature with the development of many glands and lobules. The rate of breast growth varies and is different for each young woman. Generally, there are 5 stages of breast development in girls.

Each month, women have hormone changes that make up the normal menstrual cycle. Estrogen is made by the ovaries in the first half of the menstrual cycle. It stimulates the growth of milk ducts in the breasts. The increasing level of estrogen leads to ovulation halfway through the cycle. In the second half of the cycle, the hormone progesterone takes over. It stimulates the formation of the milk glands. These hormones are believed to be responsible for the cyclical changes that many women have in their breasts just before menstruation. These include swelling, pain, and soreness. 041b061a72


Hey guys! We accept all reviews good and bad.
Group Page: Groups_SingleGroup
bottom of page